Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
Open Access
- 1 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Rheumatology International
- Vol. 32 (2), 295-299
- https://doi.org/10.1007/s00296-011-2096-3
Abstract
Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.Keywords
This publication has 29 references indexed in Scilit:
- Factors That Influence Adherence and Strategies to Maintain Adherence to Injected Therapies for Patients With Multiple SclerosisJournal of Neuroscience Nursing, 2010
- Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical reviewJournal of the American Academy of Dermatology, 2009
- Mechanisms of Adverse Drug Reactions to BiologicsHandbook of Experimental Pharmacology, 2009
- Anakinra for Rheumatoid Arthritis: A Systematic ReviewThe Journal of Rheumatology, 2009
- Mast cells and eosinophils: the two key effector cells in allergic inflammationInflammation Research, 2009
- Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.2008
- Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective studyRheumatology, 2008
- Antiallergic Anti-Inflammatory Effects of H1-Antihistamines in HumansClinical allergy and immunology, 2002
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Physiologic role of interleukin-1 receptor antagonistArthritis Research & Therapy, 2000